98 results on '"Rokutanda, N."'
Search Results
2. 68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)
- Author
-
Valle, J.W., primary, Qin, S., additional, Antonuzzo, L., additional, Tougeron, D., additional, Lee, C-K., additional, Tan, B.J., additional, Ikeda, M., additional, Guthrie, V., additional, McCoon, P., additional, Lee, Y.S., additional, Rokutanda, N., additional, Żotkiewicz, M., additional, Cohen, G., additional, and Oh, D-Y., additional
- Published
- 2022
- Full Text
- View/download PDF
3. 78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)
- Author
-
Oh, D-Y., primary, He, A.R., additional, Qin, S., additional, Chen, L-T., additional, Okusaka, T., additional, Vogel, A., additional, Kim, J.W., additional, Lee, T., additional, Lee, M.A., additional, Kitano, M., additional, Burris, H.A., additional, Bouattour, M., additional, Tanasanvimon, S., additional, Zaucha, R.E., additional, Avallone, A., additional, Cundom, J.E., additional, Rokutanda, N., additional, Żotkiewicz, M., additional, Cohen, G., additional, and Valle, J.W., additional
- Published
- 2022
- Full Text
- View/download PDF
4. 91P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)
- Author
-
Antonuzzo, L., primary, Takahashi, H., additional, Park, J.O., additional, Sookprasert, A., additional, Gillmore, R., additional, Yang, S-S., additional, Cundom, J.E., additional, Petrova, M., additional, Vaccaro, G.M., additional, Holmblad, M., additional, Xiong, J., additional, Heider, K., additional, Rokutanda, N., additional, and Oh, D-Y., additional
- Published
- 2022
- Full Text
- View/download PDF
5. 86P Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase III TOPAZ-1 study
- Author
-
He, A.R., primary, Valle, J.W., additional, Lee, C-K., additional, Ikeda, M., additional, Potemski, P., additional, Morizane, C., additional, Cundom, J.E., additional, Tougeron, D., additional, Dayyani, F., additional, Rokutanda, N., additional, Xiong, J., additional, Cohen, G., additional, and Oh, D-Y., additional
- Published
- 2022
- Full Text
- View/download PDF
6. 57P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)
- Author
-
Antonuzzo, L., primary, Takahashi, H., additional, Park, J.O., additional, Sookprasert, A., additional, Gillmore, R., additional, Yang, S-S., additional, Cundom, J.E., additional, Petrova, M., additional, Vaccaro, G.M., additional, Holmblad, M., additional, Xiong, J., additional, Heider, K., additional, Rokutanda, N., additional, and Oh, D-Y., additional
- Published
- 2022
- Full Text
- View/download PDF
7. 56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)
- Author
-
Oh, D-Y., primary, He, A.R., additional, Qin, S., additional, Chen, L-T., additional, Okusaka, T., additional, Vogel, A., additional, Kim, J.W., additional, Suksombooncharoen, T., additional, Lee, M.A., additional, Kitano, M., additional, Burris, H.A., additional, Bouattour, M., additional, Tanasanvimon, S., additional, Zaucha, R.E., additional, Avallone, A., additional, Cundom, J.E., additional, Rokutanda, N., additional, Watras, M., additional, Cohen, G., additional, and Valle, J.W., additional
- Published
- 2022
- Full Text
- View/download PDF
8. PD-8 Outcomes by disease status in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study
- Author
-
Okusaka, T., primary, Kitano, M., additional, Chen, M., additional, Chen, J., additional, Ostwal, V., additional, McNamara, M., additional, Breder, V., additional, Petrova, M., additional, Buchschacher, G., additional, Rokutanda, N., additional, Xiong, J., additional, Cohen, G., additional, and Oh, D., additional
- Published
- 2022
- Full Text
- View/download PDF
9. O-1 Outcomes by primary tumour location in patients with advanced biliary tract cancer treated with durvalumab or placebo plus gemcitabine and cisplatin in the phase 3 TOPAZ-1 study
- Author
-
He, A., primary, Valle, J., additional, Lee, C., additional, Ikeda, M., additional, Potemski, P., additional, Morizane, C., additional, Cundom, J., additional, Tougeron, D., additional, Dayyani, F., additional, Rokutanda, N., additional, Xiong, J., additional, Cohen, G., additional, and Oh, D., additional
- Published
- 2022
- Full Text
- View/download PDF
10. 102P Potentially prognostic factors of overall survival in advanced biliary tract cancer in the randomised phase III TOPAZ-1 study
- Author
-
He, A.R., Bouattour, M., Gupta, V.G., Evesque, L., Zhen, D.B., Park, J.O., Sookprasert, A., Salvatierra, A., Vaccaro, G.M., Oh, S.C., Ostoich, S.A., Satoh, T., Żotkiewicz, M., Rokutanda, N., Kim, H., and Oh, D-Y.
- Published
- 2023
- Full Text
- View/download PDF
11. Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”: [Annals of Oncology 33 (2022) S1462-S1463]
- Author
-
Oh, D., He, A.R., Qin, S., Chen, L., Okusaka, T., Vogel, A., Kim, J.W., Suksombooncharoen, T., Lee, M.A., Kitano, M., Burris, H.A., Bouattour, M., Tanasa, S., Zaucha, R.E., Avallone, A., Cundom, J.E., Rokutanda, N., Żotkiewicz, M., Cohen, G., and Valle, J.W.
- Published
- 2023
- Full Text
- View/download PDF
12. PCN299 Understanding the Patient Experience of Biliary TRACT Cancer: A Qualitative Patient Interview Study
- Author
-
Patel, N., primary, Lie, X., additional, Gwaltney, C., additional, Rokutanda, N., additional, Barzi, A., additional, Melisi, D., additional, Macarulla, T., additional, Ueno, M., additional, Meyers, O., additional, Workman, C., additional, Bachini, M., additional, and Cohen, G., additional
- Published
- 2020
- Full Text
- View/download PDF
13. A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
- Author
-
Oh, D.-Y., primary, Chen, L.-T., additional, He, A.R., additional, Okusaka, T., additional, Qin, S., additional, Chin, S., additional, Rokutanda, N., additional, Uchinda, H., additional, Vogel, A., additional, Valle, J.W., additional, and Kim, H., additional
- Published
- 2019
- Full Text
- View/download PDF
14. 831TiP - A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
- Author
-
Oh, D.-Y., Chen, L.-T., He, A.R., Okusaka, T., Qin, S., Chin, S., Rokutanda, N., Uchinda, H., Vogel, A., Valle, J.W., and Kim, H.
- Published
- 2019
- Full Text
- View/download PDF
15. Abstract P3-06-29: Change of circulating tumor cells before and after neoadjuvant chemotherapy in patients with primary breast cancer
- Author
-
Horiguchi, J, primary, Takata, D, additional, Rokutanda, N, additional, Nagaoka, R, additional, Tokiniwa, H, additional, Tozuka, K, additional, Sato, A, additional, Kikuchi, M, additional, Oyama, T, additional, and Takeyoshi, I, additional
- Published
- 2012
- Full Text
- View/download PDF
16. Abstract P2-05-07: Comparison of hormone receptor and HER-2 expression in primary breast cancers and sentinel lymph node metastases
- Author
-
Rokutanda, N, primary, Horiguchi, J, additional, Takata, D, additional, Nagaoka, R, additional, Sato, A, additional, Tokiniwa, H, additional, Tozuka, K, additional, Uchida, S, additional, and Takeyoshi, I, additional
- Published
- 2012
- Full Text
- View/download PDF
17. 289 Comparison of HER-2 and Hormone Receptor Expression in Primary Breast Cancers and Metastases
- Author
-
Rokutanda, N., primary, Horiguchi, J., additional, Kikuchi, M., additional, Takata, D., additional, Nagaoka, R., additional, Sato, A., additional, Tokiniwa, H., additional, Tozuka, K., additional, Iino, Y., additional, and Takeyoshi, I., additional
- Published
- 2012
- Full Text
- View/download PDF
18. 481 Effect of Radiation Therapy on Local Control in Patients with Positive Surgical Margins After Breast-conserving Surgery
- Author
-
Nagaoka, R., primary, Horiguchi, J., additional, Takata, D., additional, Rokutanda, N., additional, Satou, A., additional, Tokiniwa, H., additional, Toduka, K., additional, Kikuchi, M., additional, and Takeyoshi, I., additional
- Published
- 2012
- Full Text
- View/download PDF
19. 288 Changes in Estrogen Receptor (ER), Progesterone Receptor (PgR) and HER2/neu Status During Primary Systemic Chemotherapy in Breast Cancer
- Author
-
Tozuka, K., primary, Horiguchi, J., additional, Takata, D., additional, Rokutanda, N., additional, Nagaoka, R., additional, Tokiniwa, H., additional, Kikuchi, M., additional, Satou, A., additional, and Takeyoshi, I., additional
- Published
- 2012
- Full Text
- View/download PDF
20. 604 The Management of Papillary Lesions of the Breast Diagnosed Using Core Needle Biopsies
- Author
-
Tokiniwa, H., primary, Horiguchi, J., additional, Takata, D., additional, Rokutanda, N., additional, Nagaoka, R., additional, Sato, A., additional, Tozuka, K., additional, Iino, Y., additional, Oyama, T., additional, and Takeyoshi, I., additional
- Published
- 2012
- Full Text
- View/download PDF
21. 429 Circulating Tumour Cells Before and After Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer
- Author
-
Horiguchi, J., primary, Takata, D., additional, Rokutanda, N., additional, Nagaoka, R., additional, Sato, A., additional, Tokiniwa, H., additional, Tozuka, K., additional, Kikuchi, M., additional, Iino, Y., additional, and Takeyoshi, I., additional
- Published
- 2012
- Full Text
- View/download PDF
22. Comparative study of hormone receptor status and HER2 expression between primary and recurrent breast cancer.
- Author
-
Rokutanda, N., primary, Horiguchi, J., additional, Takata, D., additional, Nagaoka, R., additional, Sato, A., additional, Odawara, H., additional, Tokiniwa, H., additional, Tozuka, K., additional, and Takeyoshi, I., additional
- Published
- 2011
- Full Text
- View/download PDF
23. 53 Chemotherapy-induced amenorrhea and adjuvant endocrine therapy for premenopausal women with early breast cancer
- Author
-
Rokutanda, N., primary, Horiguchi, J., additional, Koibuchi, Y., additional, Kikuchi, M., additional, Nagaoka, R., additional, Sato, A., additional, Odawara, H., additional, Tokiniwa, H., additional, Iino, Y., additional, and Takeyoshi, I., additional
- Published
- 2010
- Full Text
- View/download PDF
24. 537 Changes of breast cancer incidence and trend among Japanese young women for the period 1972–2007
- Author
-
Koibuchi, Y., primary, Horiguchi, J., additional, Kikuchi, M., additional, Nagaoka, R., additional, Rokutanda, N., additional, Sato, A., additional, Odawara, H., additional, Tokiniwa, H., additional, Takeyoshi, I., additional, and Iino, Y., additional
- Published
- 2010
- Full Text
- View/download PDF
25. 166 Topoisomerase IIa expression correlates with prognostic factors in invasive breast cancer
- Author
-
Tokiniwa, H., primary, Horiguchi, J., additional, Koibuchi, Y., additional, Rokutanda, N., additional, Nagaoka, R., additional, Sato, A., additional, Odawara, H., additional, Oyama, T., additional, Iino, Y., additional, and Takeyoshi, I., additional
- Published
- 2010
- Full Text
- View/download PDF
26. 50 Neoadjuvant trastuzumab therapy with or without anthracycline containing chemotherapy for HER2-positive primary breast cancer
- Author
-
Horiguchi, J., primary, Koibuchi, Y., additional, Rokutanda, N., additional, Nagaoka, R., additional, Sato, A., additional, Odawara, H., additional, Tokiniwa, H., additional, Kikuchi, M., additional, Iino, Y., additional, and Takeyoshi, I., additional
- Published
- 2010
- Full Text
- View/download PDF
27. 202 Activation of breast cancer cell proliferation by ROR-alpha through aromatase promoter
- Author
-
Odawara, H., primary, Horiguchi, J., additional, Iwasaki, T., additional, Koibuchi, Y., additional, Rokutanda, N., additional, Miyazaki, W., additional, Tokiniwa, H., additional, Iino, Y., additional, Koibuchi, N., additional, and Takeyoshi, I., additional
- Published
- 2010
- Full Text
- View/download PDF
28. Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer
- Author
-
Horiguchi, J., primary, Koibuchi, Y., additional, Rokutanda, N., additional, Nagaoka, R., additional, Kikuchi, M., additional, Sato, A., additional, Ishikawa, Y., additional, Odawara, H., additional, Iino, Y., additional, and Takeyoshi, I., additional
- Published
- 2007
- Full Text
- View/download PDF
29. Predicting axillary lymph node involvement in breast cancer patients by ultrasonography
- Author
-
Rokutanda, N., primary, Horiguchi, J., additional, Koibuchi, Y., additional, Nagaoka, R., additional, Iino, Y., additional, and Takeyoshi, I., additional
- Published
- 2007
- Full Text
- View/download PDF
30. Primary Squamous Cell Carcinoma of the Breast During Lactation: a Case Report
- Author
-
Rokutanda, N., primary
- Published
- 2000
- Full Text
- View/download PDF
31. Tamoxifen activates CYP3A4 and MDR-1 genes through steroid and xenobiotic receptor (SXR) in breast cancer cells
- Author
-
Nagaoka, R., Iwasaki, T., Rokutanda, N., Takeshita, A., Koibuchi, Y., Horiguchi, J., Iino, Y., Koibuchi, N., and Morishita, Y.
- Published
- 2006
- Full Text
- View/download PDF
32. Potentiation of estrogen receptor-mediated transcription by steroid and xenobiotic receptor (SXR) in breast cancer cells
- Author
-
Rokutanda, N., Iwasaki, T., Nagaoka, R., Miyazaki, W., Takeshita, A., Koibuchi, Y., Horiguchi, J., Iino, Y., Morishita, Y., and Koibuchi, N.
- Published
- 2006
- Full Text
- View/download PDF
33. Comparison of hormone receptor and HER-2 expression in primary breast cancers and sentinel lymph node metastases.
- Author
-
Rokutanda, N., Horiguchi, J., Takata, D., Nagaoka, R., Sato, A., Tokiniwa, H., Tozuka, K., Uchida, S., and Takeyoshi, I.
- Subjects
- *
ESTROGEN receptors , *PROGESTERONE receptors , *HER2 protein , *METASTASIS , *LYMPH nodes - Abstract
Background: Recently, it is a hot topic that the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor type 2 (HER2) may differ between the primary tumors and the paired recurrent metastatic tumors. On the other hand, the concordance of the ER, PR, and HER2 status between the primary tumor and ipsilateral axillary lymph node metastases is reported to be high in previous study. However, in these reports, the majority of lymph nodes metastases examined are macrometastases obtained from axillary lymph node dissection. The aim of the present study is to compare the ER, PR, and HER2 status of the primary breast tumors with that of sentinel lymph node micrometastases and macrometastases. Methods: A total of 770 breast cancer patients underwent sentinel lymph node biopsy between 2006 and 2010 at our hospital. Among them, 87 patients who had only one node positive were eligible for our study. ER, PR, and HER2 status were determined by immunohistochemistry (IHC) and/or FISH. Result: We analyzed 76 patients with 50(66%) patients with macrometastasesn and 26 (34%) micrometastases, except 11 cases those were indeterminate for IHC. ER status of primary tumor and the paired metastatic lymph node were almost full concordance except one case, in which ER was negative in primary tumor but ER was positive in lymph node. Discordance for PR was 15.8% (n = 12). Among these, six patients had PR-positive on primary and PR-negative in lymph node while six patients had PR-negative in primary and PR-positive in lymph node. Discordance for HER2 between primary tumor and metastatic lymph node was 5.3% (n = 4). Among these, three had negative in primaries and positive in lymph nodes while one had positive in primary and negative in lymph node. A discordance between primary and lymph node in HER2, ER, or PR status was observed in 14 of 67 (18.4%) cases. Conclusions: The concordance in HER2, ER, and PR was high between the primary tumor and sentinel lymph nodes. However some cases had discordance of receptor status and these result may cause of discordance for distant metastases or poor prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
34. Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study
- Author
-
Chad Gwaltney, Xandra Lie, Afsaneh Barzi, Melinda Bachini, Oren Meyers, Makoto Ueno, Nana Rokutanda, Teresa Macarulla, Nikunj Patel, Christina Workman, G. Cohen, Davide Melisi, Seung Tae Kim, Institut Català de la Salut, [Patel N] AstraZeneca, 1 Medimmune Way, Gaithersburg, MD 20878, USA. [Lie X] IQVIA, Amsterdam, The Netherlands . [Gwaltney C] Gwaltney Consulting, Westerly, RI, USA. [Rokutanda N] Cohen AstraZeneca, Gaithersburg, MD, USA. [Barzi A] City of Hope Comprehensive Cancer Center, Duarte, CA, USA. [Melisi D] Digestive Molecular Clinical Oncology Unit, Università degli Studi di Verona, Verona, Italy. Experimental Cancer Medicine Unit, Azienda Ospedaliera Integrata di Verona, Verona, Italy. [Macarulla T] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Abdominal pain ,medicine.medical_specialty ,Health Policy, Planning and Management::Health Administration::Health Evaluation [PUBLIC HEALTH] ,Pacients - Satisfacció ,Disease ,Affect (psychology) ,Quality of life ,Qualitative research ,Patient experience ,Medicine ,neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias del tracto biliar [ENFERMEDADES] ,Original Research ,ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida [ATENCIÓN DE SALUD] ,Biliary tract cancer ,business.industry ,Cognition ,Interview study ,Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Biliary Tract Neoplasms [DISEASES] ,Políticas, Planificación y Administración en salud::administración en salud::evaluación en salud [SALUD PÚBLICA] ,Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life [HEALTH CARE] ,Oncology ,Tracte biliar - Càncer ,Physical therapy ,medicine.symptom ,business ,Qualitat de vida - Avaluació - Abstract
Cáncer del tracto biliar; Estudio de entrevista; Investigación cualitativa Càncer del tracte biliar; Estudi d'entrevista; Recerca qualitativa Biliary tract cancer; Interview study; Qualitative research Introduction Patients living with biliary tract cancer (BTC) experience a decline in health-related quality of life (HRQoL). This study aimed to obtain a comprehensive understanding of the patient experience of BTC-related signs/symptoms and the impacts of these on daily functioning and HRQoL. Methods Patients with BTC participated in qualitative semi-structured concept elicitation interviews. Signs/symptoms and impacts of BTC were initially explored by targeted literature searches and interviews with five clinicians. Patient interviews were transcribed and coded using qualitative research software. Concept saturation was assessed over five interview waves. A sign/symptom or impact was defined as “salient” if mentioned by ≥ 50% of patients, with a mean disturbance rating of ≥ 5 (0–10 scale). A conceptual model of the patient experience of BTC-related signs/symptoms and impacts was produced. Results Twenty-three patients from the USA (78% women; median age: 54 years), diagnosed as having early (n = 3), locally advanced (n = 11) or metastatic (n = 9) disease, were interviewed. Sixty-six signs/symptoms and 12 impacts were identified. Of these, 46 signs/symptoms and 8 impacts were not identified from the targeted literature or clinician interviews. Concept saturation was reached by the fourth of five interview waves. Fourteen disease-related signs/symptoms (including fatigue/lack of energy, abdominal pain, lack of appetite, insomnia and diarrhoea) and three impacts (physical, emotional and cognitive impacts) were deemed “salient”. The conceptual model included 50 signs/symptoms and 12 impacts. Conclusion Patients with BTC reported a range of signs/symptoms and impacts that negatively affect daily functioning and HRQoL. This project was funded by AstraZeneca, Gaithersburg, MD, USA. Research and publication fees are funded by the study sponsor.
- Published
- 2021
35. Change of circulating tumor cells before and after neoadjuvant chemotherapy in patients with primary breast cancer.
- Author
-
Horiguchi, J., Takata, D., Rokutanda, N., Nagaoka, R., Tokiniwa, H., Tozuka, K., Sato, A., Kikuchi, M., Oyama, T., and Takeyoshi, I.
- Subjects
- *
TUMORS , *CANCER invasiveness , *METASTASIS , *BREAST cancer patients , *DRUG therapy - Abstract
Background: Circulating tumor cells (CTCs) in peripheral blood may represent the possible presence of early tumor dissemination. However, relatively few studies were designed to investigate the change of CTC status by adjuvant chemotherapy in operable breast cancer patients. Patients and methods: Peripheral blood (7.5ml) was collected from 95 patients with stage II/III breast cancer before neoadjuvant chemotherapy (NAC). NAC consisted of anthracycline and paclitaxel chemotherapy and additional trastuzumab treatment for patients with HER2-positive tumors. Results: The average age of patients was 52.6 year old (median 52.0). One or more CTCs were detected in 18 (18.9%) of 95 patients. CTCs were detected in 6 (12.0%) of 50 patients with clinical stage II disease and 12 (26.7%) of 45 patients with clinical stage III disease. According to tumor subtypes, CTCs were detected in 5 (17.9%) of 28 patients with hormone receptor (HR)-positive and HER2-negative tumors (L subtype), 3 (12.5%) of 24 patients with HR-positive and HER2-positive tumors (L-H subtype), 4 (22.2%) of 18 patients with HR-negative and HER2-positive tumors (H subtype), and 6 (24.0%) of 25 patients with HR-negative and HER2-negative tumors (TN subtype). After NAC, 17 (94.4%) of 18 patients who were CTC-positive before chemotherapy changed into negative status. 30 (31.6%) of 95 patients had a pathologic complete response (pCR) after NAC. There was no correlation between CTC status before NAC and pathological response. At the median follow up of 27 months, distant metastasis was observed in 9 patients (9.5%). Patients with clinical stage III, TN subtype, or non-pCR had a significantly worse disease-free survival (DFS). However, CTC status before NAC was not a significant prognostic factor. Conclusion: NAC has a significant impact on CTC status irrespective of tumor subtypes. CTC status before NAC was not a significant prognostic factor in this study. The reason of which may be that most of patients showing positive for CTCs before NAC have changed into negative after NAC. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
36. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
- Author
-
Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, Kitano M, Lee CK, Kim JW, Chen MH, Suksombooncharoen T, Ikeda M, Lee MA, Chen JS, Potemski P, Burris HA 3rd, Ostwal V, Tanasanvimon S, Morizane C, Zaucha RE, McNamara MG, Avallone A, Cundom JE, Breder V, Tan B, Shimizu S, Tougeron D, Evesque L, Petrova M, Zhen DB, Gillmore R, Gupta VG, Dayyani F, Park JO, Buchschacher GL Jr, Rey F, Kim H, Wang J, Morgan C, Rokutanda N, Żotkiewicz M, Vogel A, and Valle JW
- Subjects
- Humans, Male, Female, Middle Aged, Double-Blind Method, Aged, Adult, Survival Rate, Cisplatin administration & dosage, Cisplatin therapeutic use, Gemcitabine, Deoxycytidine analogs & derivatives, Deoxycytidine administration & dosage, Deoxycytidine therapeutic use, Biliary Tract Neoplasms drug therapy, Biliary Tract Neoplasms mortality, Biliary Tract Neoplasms pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal adverse effects
- Abstract
Background: In the preplanned interim analysis of the TOPAZ-1 study, durvalumab plus gemcitabine-cisplatin significantly improved overall survival versus placebo plus gemcitabine-cisplatin in participants with advanced biliary tract cancer. We aimed to report updated overall survival and safety data from TOPAZ-1 with additional follow-up and data maturity beyond the interim analysis., Methods: TOPAZ-1 was a phase 3, randomised, double-masked, placebo-controlled, global study done at 105 sites in 17 countries. Participants aged 18 years or older with unresectable, locally advanced, or metastatic biliary tract cancer were randomly assigned (1:1) to durvalumab plus gemcitabine-cisplatin or placebo plus gemcitabine-cisplatin using a computer-generated randomisation scheme, stratified by disease status and primary tumour location. Participants received durvalumab (1500 mg) or placebo on day 1 of each cycle every 3 weeks for up to eight cycles, plus gemcitabine (1000 mg/m
2 ) and cisplatin (25 mg/m2 ) intravenously on days 1 and 8 of each cycle every 3 weeks for up to eight cycles, followed by durvalumab (1500 mg) or placebo monotherapy every 4 weeks until disease progression or other discontinuation criteria were met. Investigators and participants were masked to study treatment. The primary endpoint was overall survival. TOPAZ-1 met its primary endpoint at the preplanned interim analysis, and the study is active but no longer recruiting participants. Updated overall survival and safety data from TOPAZ-1, with additional follow-up (data cutoff Feb 25, 2022) and data maturity beyond the interim analysis, are reported here. Efficacy was assessed in the full analysis set (all randomly assigned participants). Safety was assessed in the safety analysis set (all participants who received at least one dose of study treatment). The TOPAZ-1 study is registered with ClinicalTrials.gov, NCT03875235., Findings: From April 16, 2019, to Dec 11, 2020, 914 participants were enrolled, 685 of whom were randomly assigned (341 to the durvalumab plus gemcitabine-cisplatin group and 344 to the placebo plus gemcitabine-cisplatin group). 345 (50%) participants were male and 340 (50%) were female. Median follow-up at the updated data cutoff was 23·4 months (95% CI 20·6-25·2) in the durvalumab plus gemcitabine-cisplatin group and 22·4 months (21·4-23·8) in the placebo plus gemcitabine-cisplatin group. At the updated data cutoff, 248 (73%) participants in the durvalumab plus gemcitabine-cisplatin group and 279 (81%) participants in the placebo plus gemcitabine-cisplatin group had died (median overall survival 12·9 months [95% CI 11·6-14·1] vs 11·3 months [10·1-12·5]; hazard ratio 0·76 [95% CI 0·64-0·91]). Kaplan-Meier-estimated 24-month overall survival rates were 23·6% (95% CI 18·7-28·9) in the durvalumab plus gemcitabine-cisplatin group and 11·5% (7·6-16·2) in the placebo plus gemcitabine-cisplatin group. Maximum grade 3 or 4 adverse events occurred in 250 (74%) of 338 participants in the durvalumab plus gemcitabine-cisplatin group and 257 (75%) of 342 in the placebo plus gemcitabine-cisplatin group. The most common maximum grade 3 or 4 treatment-related adverse events were decreased neutrophil count (70 [21%] vs 86 [25%]), anaemia (64 [19%] vs 64 [19%]), and neutropenia (63 [19%] vs 68 [20%])., Interpretation: Durvalumab plus gemcitabine-cisplatin showed robust and sustained overall survival benefit with no new safety signals. Findings continue to support the regimen as a standard of care for people with untreated, advanced biliary tract cancer., Funding: AstraZeneca., Competing Interests: Declaration of interests D-YO reports advisory fees from Arcus Biosciences, Aslan Pharmaceuticals, AstraZeneca, Basilea, Bayer, BeiGene, Bristol Myers Squibb/Celgene, Genentech/Roche, Halozyme, IQVIA, Merck Serono, Novartis, Taiho Pharmaceutical, Turning Point Therapeutics, Yuhan, and Zymeworks; and institutional research funding from Array BioPharma, AstraZeneca, BeiGene, Eli Lilly, Handok, MSD, Novartis, and Servier. ARH reports consulting fees from AstraZeneca, Bristol Myers Squibb, and Genentech/Roche; research funding from Genentech and Merck; and speakers bureau fees from Eisai and Bristol Myers Squibb. MB reports consulting fees from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, MSD, Roche, and Sirtex Medical; speakers bureau fees from Bayer, Eisai, and Roche; and support for travel and attending meetings from AstraZeneca, Bayer, and Sirtex Medical. TO reports advisory fees from AstraZeneca, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, Incyte, Meiji Seika Pharma, Mundipharma, Nihon Servier, Nippon Shinyaku, Pfizer, Taiho Pharmaceutical, and Takara Bio; and speaker fees from AstraZeneca, Baxter, Bayer, Bristol Myers Squibb, Chugai Pharma, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, MSD, Nihon Servier, Novartis, Ono Pharmaceutical, Taiho Pharmaceutical, Teijin Pharma, and Yakult Honsha. L-TC reports personal speaker fees from Bristol Myers Squibb, CStone, Eli Lilly, Ipsen, Ono Pharmaceutical, Novartis, PharmaEngine, and TTY; fees for medical monitoring for clinical trials for Taivex; fees received as a data and safety monitoring committee member for clinical trials for OBI Pharma; advisory fees from AstraZeneca, MSD, and SynCoreBio; speaker fees from AstraZeneca, HuniLife Biotechnology, Ono Pharmaceutical, ScinoPharm Taiwan, SynCoreBio, and TTY; and research funding from Celgene. MK reports research funding from AbbVie and Takeda; and honoraria from EA Pharma and AstraZeneca. JWK reports research funding from inno.N and Jeil Pharmaceutical; and consulting fees from AstraZeneca, BeiGene, BeyondBio, Bristol Myers Squibb/Celgene, Eisai, GC Cell, MSD Ono, Sanofi-Aventis, Servier, and TCUBEit. TS reports speaker fees from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Baxter, Eli Lilly, Mundipharma (Thailand), Janssen, MSD, Novartis, Roche, and Takeda; and advisory fees from Novartis and Roche. MI reports grant or research support from Aslan Pharmaceuticals, AstraZeneca, Bayer, Bristol Myers Squibb, Chiome Bioscience, Chugai Pharma, Delta-Fly Pharma, EA Pharma, Eisai, Eli Lilly Japan, J-Pharma, Merck, Merus NV, Nihon Servier, Novartis, Ono Pharmaceutical, Pfizer, Takeda, and Yakult; fees or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Astellas Pharma, Bayer, Bristol Myers Squibb, Chugai Pharma, Eisai, Eli Lilly Japan, MSD, Nihon Servier, Novartis, Otsuka, Dainippon Sumitomo Pharma, Taiho Pharmaceutical, Takeda, Teijin Pharma, and Yakult; and fees for participation on a data safety monitoring board or advisory board from Aslan Pharmaceuticals, Bayer, Bristol Myers Squibb, Chugai Pharma, Eisai, Eli Lilly Japan, GlaxoSmithKline, Nihon Servier, Novartis, and Takeda. J-SC reports grant or research support from Astellas Pharma, AstraZeneca, Bristol Myers Squibb, Janssen, Eli Lilly, Merck KGaA, MSD, MSD Oncology, Oncologie, Ono Pharmaceutical, Roche, Senhwa Biosciences, SynCore, and TTY; and consulting fees from Ono Pharmaceutical. PP reports personal fees for an advisory board from AstraZeneca, Sanofi-Aventis, Bristol Myers Squibb, Janssen Oncology, MSD, Pierre Fabre, Roche, and Servier; personal fees as an invited speaker from AstraZeneca, Ipsen, Pierre Fabre, and Merck; and being a principal investigator for AstraZeneca and Roche. HAB reports research funding from AbbVie, Agios, Arch Pharmalabs, ARMO BioSciences, Array BioPharma, Arvinas, AstraZeneca, Bayer, BIND Therapeutics, BioAtla, BioMed Valley Discoveries, Biotheryx, Boehringer Ingelheim, Bristol Myers Squibb, CALGB, CicloMed, Coordination Pharmaceuticals, CytomX, eFFECTOR Therapeutics, Eli Lilly, EMD Serono, Foundation Medicine, Gossamer Bio, Gilead Sciences, GlaxoSmithKline, Harpoon Therapeutics, Incyte, Infinity Pharmaceuticals, Janssen, Jiangsu Hengrui Pharmaceuticals, Jounce Therapeutics, Kymab, MacroGenics, MedImmune, Merck, Millennium/Takeda, miRNA Therapeutics, Moderna, NGM Bio, Novartis, Pfizer, Revolution Medicine, Roche/Genentech, Ryvu Therapeutics, Seattle Genetics, Tesaro, TG Therapeutics, Verastem Oncology, Vertex Pharmaceuticals, XBiotech, and Zymeworks; and consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Forma Therapeutics, Grail, Incyte, Novartis, Pfizer, and Vincerx Pharma. VO reports grant or research support from Dr Reddy's Laboratories and Zydus Cadila; institutional fees for advisory board participation from AstraZeneca, Panacea Biotec, Dr Reddy's Laboratories, and Zydus Cadila; travel reimbursement as an invited speaker from AstraZeneca; other institutional financial interests with Alkem Laboratories, Eisai, Intas Pharmaceuticals, and Micro Labs; and non-financial interests with the Indian Association of Supportive Care in Cancer. ST reports honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, MSD, Novartis, and Roche; speaker fees from Bristol Myers Squibb, Ipsen, and Novartis; and non-financial interests with AstraZeneca, Bristol Myers Squibb, Ipsen, Janssen, and Roche. CM reports institutional grant or research support from AstraZeneca, Daiichi Sankyo, Eisai, J-Pharma, Hitachi, Merck BioReliance, MSD, Kyowa Kirin, Ono Pharmaceutical, Taiho Pharmaceutical, and Yakult Honsha; personal fees for advisory board participation from AstraZeneca, Boehringer Ingelheim, Merck BioReliance, MSD, Servier, Taiho Pharmaceutical, and Yakult; and personal fees received as an invited speaker from AstraZeneca, Eisai, Kyowa Kirin, MSD, Novartis, Servier, Taiho Pharmaceutical, Teijin Pharma, and Yakult Honsha. REZ reports speaker fees from Bristol Myers Squibb, Ipsen, and Novartis; and travel grants from Pierre Fabre. MGM reports grant or research support from Ipsen, NuCana, and Servier; consulting fees from AstraZeneca and Incyte; and honoraria from Advanced Accelerator Applications and AstraZeneca. AA reports research funding from Amgen, Bayer, and Bristol Myers Squibb; and advisory fees from AstraZeneca, Amgen, Eisai, and MSD. JEC reports advisory fees from MSD; and fees as an invited speaker for AstraZeneca, Boehringer Ingelheim, Takeda, and Roche. VB reports consulting fees from Bayer, Bristol Myers Squibb Russia, Eisai, MSD, Novartis, Pfizer, Roche Russia, and Takeda; and travel expenses from Bayer, Bristol Myers Squibb Russia, MSD, and Roche Russia. BT reports research funding from Adaptimmune, AstraZeneca, Bristol Myers Squibb, and Exelixis. SS reports grant or research support from Delta-Fly Pharma and Incyte. DT reports personal fees for advisory board participation from Amgen, AstraZeneca, MSD, Pierre Fabre, Roche, Sanofi, and Servier. LE reports personal fees for advisory board participation from Amgen, Merk, MSD, and Servier. MP reports personal fees for advisory board participation from Roche and Servier; personal fees as an invited speaker from AstraZeneca, Ewopharma, and Takeda; and non-financial interests with AstraZeneca and Sanofi. DBZ reports advisory fees from Cornerstone Pharmaceuticals, Ipsen, Jazz Pharmaceuticals/Zymeworks, and QED Therapeutics; and research funding from AstraZeneca, Bayer, Bristol Meyers Squibb, Cornerstone Pharmaceuticals, Daiichi Sankyo, Eli Lily, Ipsen, Roche/Genentech, Legend Biotech, Merck, and Seagen. VGG holds stock in RPG Life Sciences and Zydus Lifesciences. FD reports grant or research support from Amgen, AstraZeneca, Bristol Myers Squibb, Exelixis, Genentech, Ipsen, Signatera, and Taiho Pharmaceutical; consulting fees from AstraZeneca, Eisai, Exelixis, Genentech, and Ipsen; and payment or honoraria from Astellas, Eisai, Exelixis, Ipsen, Servier, and Sirtex Medical. JOP reports advisory board fees from Adicet Bio, AstraZeneca, Bristol Myers Squibb (Celgene), MediRama, MedPacto, Merck Serono, and Servier; support for travel to meetings from Minneamrita Therapeutics; and grant or research support from ABL Bio, Bristol Myers Squibb (Celgene), Eutilex, MedPacto, and Servier. HK, CM, and MŻ are employees of AstraZeneca. JW and NR are employees of and hold stock in AstraZeneca. AV reports speaker fees from BeiGene, Bristol Myers Squibb, Eisai, Imaging Equipment, Incyte, Ipsen, Jiangsu Hengrui Pharmaceuticals, Eli Lilly, MSD, Novartis, Pierre Fabre, and Roche; and advisory fees from AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Daiichi Sankyo, Eisai, Ipsen, Incyte, Lilly, MSD, Pierre Fabre, Roche, and Sirtex Medical. JWV reports advisory fees from Agios, AstraZeneca, Autem Therapeutics, Baxter, Hutchison MediPharma, Image Equipment, NuCana, QED Therapeutics, Sirtex Medical, Servier, and Zymeworks; speaker fees from Incyte, Ipsen, and Mylan; and research funding from AstraZeneca and Redx. All other authors declare no competing interests., (2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)- Published
- 2024
- Full Text
- View/download PDF
37. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
- Author
-
Burris HA 3rd, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V, Blanc JF, Li J, Bachini M, Żotkiewicz M, Abraham J, Patel N, Wang J, Ali M, Rokutanda N, Cohen G, and Oh DY
- Subjects
- Humans, Double-Blind Method, Male, Female, Middle Aged, Aged, Adult, Quality of Life, Cisplatin administration & dosage, Gemcitabine, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biliary Tract Neoplasms drug therapy, Biliary Tract Neoplasms pathology, Biliary Tract Neoplasms mortality, Deoxycytidine analogs & derivatives, Deoxycytidine administration & dosage, Antibodies, Monoclonal administration & dosage, Patient Reported Outcome Measures
- Abstract
Background: In the ongoing, randomised, double-blind phase 3 TOPAZ-1 study, durvalumab, a PD-L1 inhibitor, plus gemcitabine and cisplatin was associated with significant improvements in overall survival compared with placebo, gemcitabine, and cisplatin in people with advanced biliary tract cancer at the pre-planned intermin analysis. In this paper, we present patient-reported outcomes from TOPAZ-1., Methods: In TOPAZ-1 (NCT03875235), participants aged 18 years or older with previously untreated, unresectable, locally advanced, or metastatic biliary tract cancer with an Eastern Cooperative Oncology Group performance status of 0 or 1 and one or more measurable lesions per Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) were randomly assigned (1:1) to the durvalumab group or the placebo group using a computer-generated randomisation scheme. Participants received 1500 mg durvalumab or matched placebo intravenously every 3 weeks (on day 1 of the cycle) for up to eight cycles in combination with 1000 mg/m
2 gemcitabine and 25 mg/m2 cisplatin intravenously on days 1 and 8 every 3 weeks for up to eight cycles. Thereafter, participants received either durvalumab (1500 mg) or placebo monotherapy intravenously every 4 weeks until disease progression or other discontinuation criteria were met. Randomisation was stratified by disease status (initially unresectable vs recurrent) and primary tumour location (intrahepatic cholangiocarcinoma vs extrahepatic cholangiocarcinoma vs gallbladder cancer). Patient-reported outcomes were assessed as a secondary outcome in all participants who completed the European Organisation for Research and Treatment of Cancer's 30-item Quality of Life of Cancer Patients questionnaire (QLQ-C30) and the 21-item Cholangiocarcinoma and Gallbladder Cancer Quality of Life Module (QLQ-BIL21). We calculated time to deterioration-ie, time from randomisation to an absolute decrease of at least 10 points in a patient-reported outcome that was confirmed at a subsequent visit or the date of death (by any cause) in the absence of deterioration-and adjusted mean change from baseline in patient-reported outcomes., Findings: Between April 16, 2019, and Dec 11, 2020, 685 participants were enrolled and randomly assigned, 341 to the durvalumab group and 344 to the placebo group. Overall, 345 (50%) of participants were male and 340 (50%) were female. Data for the QLQ-C30 were available for 318 participants in the durvalumab group and 328 in the placebo group (median follow-up 9·9 months [IQR 6·7 to 14·1]). Data for the QLQ-BIL21 were available for 305 participants in the durvalumab group and 322 in the placebo group (median follow-up 10·2 months [IQR 6·7 to 14·3]). The proportions of participants in both groups who completed questionnaires were high and baseline scores were mostly similar across treatment groups. For global health status or quality of life, functioning, and symptoms, we noted no difference in time to deterioration or adjusted mean changes from baseline were observed between groups. Median time to deterioration of global health status or quality of life was 7·4 months (95% CI 5·6 to 8·9) in the durvalumab group and 6·7 months (5·6 to 7·9) in the placebo group (hazard ratio 0·87 [95% CI 0·69 to 1·12]). The adjusted mean change from baseline was 1·23 (95% CI -0·71 to 3·16) in the durvalumab group and 0·35 (-1·63 to 2·32) in the placebo group., Interpretation: The addition of durvalumab to gemcitabine and cisplatin did not have a detrimental effect on patient-reported outcomes. These results suggest that durvalumab, gemcitabine, and cisplatin is a tolerable treatment regimen in patients with advanced biliary tract cancer., Funding: AstraZeneca., Competing Interests: Declaration of interests HABIII reports consulting or advisory fees from AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, FORMA Therapeutics, GRAIL, Incyte, Novartis, Pfizer, and Vincerx, and and research funding from AbbVie, Agios, Arch, ARMO Biosciences, Array BioPharma, Arvinas, AstraZeneca, Bayer, BIND Therapeutics, BioAtla, BioMed Valley, Biotheryx, Boehringer Ingelheim, Bristol-Myers Squibb, Cancer and Leukemia Group B, Ciclomed, Coordination Pharmaceuticals, CytomX, eFFECTOR Therapeutics, EMD Serono, Foundation Medicine, Gossamer Bio, Gilead Sciences, GlaxoSmithKline, Harpoon Therapeutics, Jiangsu Hengrui, Incyte, Infinity, Janssen, Jounce, Kymab, Lilly, MacroGenics, MedImmune, Merck, Millennium, Takeda, miRNA Therapeutics, Moderna, NGM Biopharmaceuticals, Novartis, Pfizer, Revolution Medicine, Roche, Genentech, Ryvu, Seattle Genetics, TESARO, TG Therapeutics, Verastem, Vertex, XBiotech, and Zymeworks. TO reports honoraria from AbbVie, AstraZeneca, Chugai, Daiichi Sankyo, Eisai, Eli Lilly Japan, Nihon Servier, Novartis, ONO, Taiho, Takeda, Teijin, and Yakult; consulting or advisory fees from AstraZeneca, Bayer Yakuhin, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Sumitomo, Eisai, Eli Lilly Japan, Incyte, Meiji Seika Pharma, Mundipharma, Nihon Servier, Nippon Shinyaku, Novartis, ONO, Pfizer, Shire, Taiho, Takara Bio, and Takeda; and research funding from AstraZeneca, Baxter, Bristol-Myers Squibb, Chugai, Sumitomo, Eisai, Eli Lilly Japan, Kyowa Hakko Kirin, Merck, Sharp, & Dohme, Nano Carrier, Novartis, ONO, Pfizer, Syneos Health, and Taiho. AV reports honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb, British Technology Group, Eisai, GlaxoSmithKline, Imaging Equipment, Incyte, Ipsen, Lilly, Merck, Novartis, Pierre Fabre, Roche, Sanofi, Servier, Sirtex, and Terumo; and consulting or advisory fees from AstraZeneca, Bayer, Bristol-Myers Squibb, British Technology Group, Eisai, GlaxoSmithKline, Imaging Equipment, Incyte, Ipsen, Lilly, Merck, Novartis, Pierre Fabre, Roche, Sanofi, Servier, Sirtex, and Terumo. HT reports honoraria from Daiichi Sankyo, Mylan, Taiho, and Yakult, and research funding from AstraZeneca, Daiichi Sankyo, and Taiho. VB reports honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb Russia, Eisai, Merck, Sharp, & Dohme, Novartis, Pfizer, Roche Russia, and Takeda, and travel or accommodation expenses from Bayer, Bristol-Myers Squibb Russia, Merck, Sharp, & Dohme, and Roche Russia. J-FB reports honoraria from AstraZeneca, Bayer, Eisai, Ipsen, Merck, Sharp, & Dohme, and Roche, and consulting or advisory fees from AstraZeneca, Bayer, Eisai, Ipsen, Merck, Sharp, & Dohme, and Roche. MB reports honoraria for participating in patient advisory boards, review of patient materials, and speaking engagements from AstraZeneca, Boehringer Ingelheim, CRC Oncology, EMD Serono, Incyte, Kinnate, Merck, QED Clinical Services, Taiho, and TriSalus. MŻ is an employee of AstraZeneca. JA was an employee of IQVIA at the time of the study and reports consulting or advisory fees from AstraZeneca. NP, JW, MA, NR, and GC are employees of, and hold stock in, AstraZeneca. D-YO reports consulting or advisory fees from ASLAN, AstraZeneca, Basilea, Bayer, BeiGene, Bristol-Myers Squibb, Celgene, Genentech, Roche, Halozyme, Merck Serono, Novartis, Taiho, Turning Point, Yuhan, and Zymeworks, and research funding from Array, AstraZeneca, BeiGene, Eli Lilly, Handok, Merck, Sharp, & Dohme, Novartis, and Servier. All other others declare no competing interests., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
38. Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
- Author
-
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Lee MA, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, Żotkiewicz M, Kurland JF, Cohen G, and Valle JW
- Subjects
- Adult, Humans, Gemcitabine, Deoxycytidine, Cisplatin, Antineoplastic Combined Chemotherapy Protocols adverse effects, Biliary Tract Neoplasms drug therapy, Bile Duct Neoplasms drug therapy
- Abstract
What Is This Summary About?: This is a summary describing the results of a Phase III study called TOPAZ-1. The study looked at treatment with durvalumab (a type of immunotherapy) and chemotherapy to treat participants with advanced biliary tract cancer (BTC). Advanced BTC is usually diagnosed at late stages of disease, when it cannot be cured by surgery. This study included participants with advanced BTC who had not received previous treatment, or had their cancer come back at least 6 months after receiving treatment or surgery that aimed to cure their disease. Participants received treatment with durvalumab and chemotherapy or placebo and chemotherapy. The aim of this study was to find out if treatment with durvalumab and chemotherapy could increase the length of time that participants with advanced BTC lived, compared with placebo and chemotherapy., What Were the Results of the Study?: Participants who took durvalumab and chemotherapy had a 20% lower chance of experiencing death at any point in the study compared with participants who received placebo and chemotherapy. The side effects experienced by participants were similar across treatment groups, and less than 12% of participants in either treatment group had to stop treatment due to treatment-related side effects., What Do the Results of the Study Mean?: Overall, these results support durvalumab and chemotherapy as a new treatment option for people with advanced BTCs. Based on the results of this study, durvalumab is now approved for the treatment of adults with advanced BTCs in combination with chemotherapy by government organizations in Europe, the United States and several other countries.
- Published
- 2023
- Full Text
- View/download PDF
39. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
- Author
-
Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Ah Lee M, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, He P, Kurland JF, Cohen G, and Valle JW
- Subjects
- Humans, Male, Female, Double-Blind Method, Middle Aged, Aged, Adult, Progression-Free Survival, Gemcitabine, Deoxycytidine analogs & derivatives, Deoxycytidine administration & dosage, Deoxycytidine therapeutic use, Deoxycytidine adverse effects, Biliary Tract Neoplasms drug therapy, Biliary Tract Neoplasms mortality, Biliary Tract Neoplasms pathology, Cisplatin administration & dosage, Cisplatin therapeutic use, Cisplatin adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects
- Abstract
BACKGROUND: Patients with advanced biliary tract cancer have a poor prognosis, and first-line standard of care (gemcitabine plus cisplatin) has remained unchanged for more than 10 years. The TOPAZ-1 trial evaluated durvalumab plus chemotherapy for patients with advanced biliary tract cancer. METHODS: In this double-blind, placebo-controlled, phase 3 study, we randomly assigned patients with previously untreated unresectable or metastatic biliary tract cancer or with recurrent disease 1:1 to receive durvalumab or placebo in combination with gemcitabine plus cisplatin for up to eight cycles, followed by durvalumab or placebo monotherapy until disease progression or unacceptable toxicity. The primary objective was to assess overall survival. Secondary end points included progression-free survival, objective response rate, and safety. RESULTS: Overall, 685 patients were randomly assigned to durvalumab (n=341) or placebo (n=344) with chemotherapy. As of data cutoff, 198 patients (58.1%) in the durvalumab group and 226 patients (65.7%) in the placebo group had died. The hazard ratio for overall survival was 0.80 (95% confidence interval [CI], 0.66 to 0.97; P=0.021). The estimated 24-month overall survival rate was 24.9% (95% CI, 17.9 to 32.5) for durvalumab and 10.4% (95% CI, 4.7 to 18.8) for placebo. The hazard ratio for progression-free survival was 0.75 (95% CI, 0.63 to 0.89; P=0.001). Objective response rates were 26.7% with durvalumab and 18.7% with placebo. The incidences of grade 3 or 4 adverse events were 75.7% and 77.8% with durvalumab and placebo, respectively. CONCLUSIONS: Durvalumab plus chemotherapy significantly improved overall survival versus placebo plus chemotherapy and showed improvements versus placebo plus chemotherapy in prespecified secondary end points including progression-free survival and objective response rate. The safety profiles of the two treatment groups were similar. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT03875235.)
- Published
- 2022
- Full Text
- View/download PDF
40. Understanding Patient Experience in Biliary Tract Cancer: A Qualitative Patient Interview Study.
- Author
-
Patel N, Lie X, Gwaltney C, Rokutanda N, Barzi A, Melisi D, Macarulla T, Ueno M, Kim ST, Meyers O, Workman C, Bachini M, and Cohen G
- Abstract
Introduction: Patients living with biliary tract cancer (BTC) experience a decline in health-related quality of life (HRQoL). This study aimed to obtain a comprehensive understanding of the patient experience of BTC-related signs/symptoms and the impacts of these on daily functioning and HRQoL., Methods: Patients with BTC participated in qualitative semi-structured concept elicitation interviews. Signs/symptoms and impacts of BTC were initially explored by targeted literature searches and interviews with five clinicians. Patient interviews were transcribed and coded using qualitative research software. Concept saturation was assessed over five interview waves. A sign/symptom or impact was defined as "salient" if mentioned by ≥ 50% of patients, with a mean disturbance rating of ≥ 5 (0-10 scale). A conceptual model of the patient experience of BTC-related signs/symptoms and impacts was produced., Results: Twenty-three patients from the USA (78% women; median age: 54 years), diagnosed as having early (n = 3), locally advanced (n = 11) or metastatic (n = 9) disease, were interviewed. Sixty-six signs/symptoms and 12 impacts were identified. Of these, 46 signs/symptoms and 8 impacts were not identified from the targeted literature or clinician interviews. Concept saturation was reached by the fourth of five interview waves. Fourteen disease-related signs/symptoms (including fatigue/lack of energy, abdominal pain, lack of appetite, insomnia and diarrhoea) and three impacts (physical, emotional and cognitive impacts) were deemed "salient". The conceptual model included 50 signs/symptoms and 12 impacts., Conclusion: Patients with BTC reported a range of signs/symptoms and impacts that negatively affect daily functioning and HRQoL., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
41. HERC2 regulates RPA2 by mediating ATR-induced Ser33 phosphorylation and ubiquitin-dependent degradation.
- Author
-
Lai Y, Zhu M, Wu W, Rokutanda N, Togashi Y, Liang W, and Ohta T
- Subjects
- HCT116 Cells, HEK293 Cells, HeLa Cells, Humans, Phosphorylation, Protein Interaction Maps, Protein Subunits metabolism, Proteolysis, Ubiquitin-Protein Ligases metabolism, Ubiquitination, Guanine Nucleotide Exchange Factors metabolism, Replication Protein A metabolism, Ubiquitin metabolism
- Abstract
Replication protein A (RPA) binds to and stabilizes single-stranded DNA and is essential for the genome stability. We reported that an E3 ubiquitin ligase, HERC2, suppresses G-quadruplex (G4) DNA by regulating RPA-helicase complexes. However, the precise mechanism of HERC2 on RPA is as yet largely unknown. Here, we show essential roles for HERC2 on RPA2 status: induction of phosphorylation and degradation of the modified form. HERC2 interacted with RPA through the C-terminal HECT domain. Ubiquitination of RPA2 was inhibited by HERC2 depletion and rescued by reintroduction of the C-terminal fragment of HERC2. ATR-mediated phosphorylation of RPA2 at Ser33 induced by low-level replication stress was inhibited by depletion of HERC2. Contrary, cells lacking HERC2 catalytic residues constitutively expressed an increased level of Ser33-phosphorylated RPA2. HERC2-mediated ubiquitination of RPA2 was abolished by an ATR inhibitor, supporting a hypothesis that the ubiquitinated RPA2 is a phosphorylated subset. Functionally, HERC2 E3 activity has an epistatic relationship with RPA in the suppression of G4 when judged with siRNA knockdown experiments. Together, these results suggest that HERC2 fine-tunes ATR-phosphorylated RPA2 levels through induction and degradation, a mechanism that could be critical for the suppression of secondary DNA structures during cell proliferation.
- Published
- 2019
- Full Text
- View/download PDF
42. HERC2 Facilitates BLM and WRN Helicase Complex Interaction with RPA to Suppress G-Quadruplex DNA.
- Author
-
Wu W, Rokutanda N, Takeuchi J, Lai Y, Maruyama R, Togashi Y, Nishikawa H, Arai N, Miyoshi Y, Suzuki N, Saeki Y, Tanaka K, and Ohta T
- Subjects
- Aminoquinolines pharmacology, Catalytic Domain, Cell Cycle, DNA Repair, DNA Replication, DNA, Single-Stranded genetics, Genomic Instability, HCT116 Cells, HEK293 Cells, HeLa Cells, Humans, Neoplasms metabolism, Oxazoles pharmacology, Phenotype, Picolinic Acids pharmacology, Protein Binding, RNA, Small Interfering metabolism, Ubiquitin-Protein Ligases, G-Quadruplexes, Guanine Nucleotide Exchange Factors metabolism, RecQ Helicases metabolism, Replication Protein A metabolism, Werner Syndrome Helicase metabolism
- Abstract
BLM and WRN are RecQ DNA helicasesessential for genomic stability. Here, we demonstrate that HERC2, a HECT E3 ligase, is critical for their functions to suppress G-quadruplex (G4) DNA. HERC2 interacted with BLM, WRN, and replication protein A (RPA) complexes during the S-phase of the cell cycle. Depletion of HERC2 dissociated RPA from BLM and WRN complexes and significantly increased G4 formation. Triple depletion revealed that HERC2 has an epistatic relationship with BLM and WRN in their G4-suppressing function. In vitro , HERC2 released RPA onto single-stranded DNA (ssDNA) rather than anchoring onto RPA-coated ssDNA. CRISPR/Cas9-mediated deletion of the catalytic ubiquitin-binding site of HERC2 inhibited ubiquitination of RPA2, caused RPA accumulation in the helicase complexes, and increased G4, indicating an essential role for E3 activity in the suppression of G4. Both depletion of HERC2 and inactivation of E3 sensitized cells to the G4-interacting compounds telomestatin and pyridostatin. Overall, these results indicate that HERC2 is a master regulator of G4 suppression that affects the sensitivity of cells to G4 stabilizers. Given that HERC2 expression is frequently reduced in many types of cancers, G4 accumulation as a result of HERC2 deficiency may provide a therapeutic target for G4 stabilizers. Significance: HERC2 is revealed as a master regulator of G-quadruplex, a DNA secondary structure that triggers genomic instability and may serve as a potential molecular target in cancer therapy. Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/22/6371/F1.large.jpg Cancer Res; 78(22); 6371-85. ©2018 AACR ., (©2018 American Association for Cancer Research.)
- Published
- 2018
- Full Text
- View/download PDF
43. Reversible Cardiomyopathy After Epirubicin Administration.
- Author
-
Koitabashi N, Ohyama Y, Tateno R, Arai M, Rokutanda N, Horiguchi J, and Kurabayashi M
- Subjects
- Aged, Antibiotics, Antineoplastic administration & dosage, Cardiomyopathies chemically induced, Cardiomyopathies complications, Cardiomyopathies diagnosis, Cardiomyopathies physiopathology, Cardiomyopathies therapy, Cardiotonic Agents administration & dosage, Echocardiography, Electrocardiography, Epirubicin administration & dosage, Female, Heart Failure diagnosis, Heart Failure drug therapy, Heart Failure etiology, Heart Failure physiopathology, Heart Ventricles pathology, Humans, Magnetic Resonance Imaging, Cine, Severity of Illness Index, Treatment Outcome, Antibiotics, Antineoplastic adverse effects, Atrial Natriuretic Factor administration & dosage, Breast Neoplasms drug therapy, Diuretics administration & dosage, Dobutamine administration & dosage, Epirubicin adverse effects, Respiration, Artificial methods
- Abstract
Anthracycline-containing chemotherapy can cause irreversible and progressive left ventricular dysfunction. Epirubicin, which is widely used for breast cancer chemotherapy, is an anthracycline that has less cardiac toxicity than doxorubicin. The present report describes the case of a 70-year-old woman with breast cancer who developed severe congestive heart failure and severe cardiac dysfunction at 6 weeks from epirubicin final administration. Left ventricular function gradually improved after intensive treatment for heart failure and recovered completely within 2 months. To the best of our knowledge, this is the first report to describe epirubicin-induced subacute reversible cardiotoxicity.
- Published
- 2015
- Full Text
- View/download PDF
44. Somatic mutations of the catalytic subunit of cyclic AMP-dependent protein kinase (PRKACA) gene in Japanese patients with several adrenal adenomas secreting cortisol [Rapid Communication].
- Author
-
Nakajima Y, Okamura T, Gohko T, Satoh T, Hashimoto K, Shibusawa N, Ozawa A, Ishii S, Tomaru T, Horiguchi K, Okada S, Takata D, Rokutanda N, Horiguchi J, Tsushima Y, Oyama T, Takeyoshi I, and Yamada M
- Subjects
- Adenoma epidemiology, Adrenal Gland Neoplasms epidemiology, Adult, Aged, Cushing Syndrome epidemiology, Cushing Syndrome genetics, Female, Humans, Japan epidemiology, Middle Aged, Neoplasms, Multiple Primary epidemiology, Neoplasms, Multiple Primary genetics, Neoplasms, Multiple Primary metabolism, Polymorphism, Restriction Fragment Length, Retrospective Studies, Adenoma genetics, Adenoma metabolism, Adrenal Gland Neoplasms genetics, Adrenal Gland Neoplasms metabolism, Cyclic AMP-Dependent Protein Kinase Catalytic Subunits genetics, Hydrocortisone metabolism, Mutation
- Abstract
Somatic mutations of the catalytic subunit of the cyclic AMP-dependent protein kinase (PRKACA) gene have recently been identified in about 35% of cortisol-producing adenomas (CPAs), with the affected patients showing overt Cushing's syndrome. Since we recently reported higher prevalence of mutations of the KCNJ5 gene and associations with autonomous cortisol secretion in Japanese aldosterone-producing adenomas than in Western countries, there might be different features of CPAs between Japan and the West. We therefore investigated mutations of the PRKACA gene in Japanese patients with several adrenal tumors secreting cortisol, including overt Cushing's syndrome, subclinical Cushing's syndrome, and aldosterone-producing adenomas (APAs) co-secreting cortisol operated on at Gunma University Hospital. Of the 13 patients with CPA who showed overt Cushing's syndrome, 3 (23%) had recurrent somatic mutations of the PRKACA gene, p.L206R (c.617 T>G), and there were no mutations in subclinical Cushing's syndrome. Among 33 APAs, 24 had somatic mutations of the KCNJ5 gene, either G151R or L168R, 11 (33%) had autonomous cortisol secretion, but there were no mutations of the PRKACA gene. We established a PCR-restriction fragment length polymorphism assay and revealed that the mutated allele was expressed at a similar level to the wild-type allele. These findings demonstrated that 1) the prevalence of Japanese patients with CPA who showed overt Cushing's syndrome and whose somatic mutations in the PRKACA gene was similar to that in Western countries, 2) the mutation might be specific for CPAs causing overt Cushing's syndrome, and 3) the mutant PRKACA allele was expressed appropriately in CPAs.
- Published
- 2014
- Full Text
- View/download PDF
45. [Phase I study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer].
- Author
-
Horiguchi J, Takata D, Rokutanda N, Nagaoka R, Tokiniwa H, Odawara H, Kikuchi M, Sato A, and Takeyoshi I
- Subjects
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms pathology, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Drug Combinations, Female, Humans, Middle Aged, Neoplasm Metastasis, Oxonic Acid administration & dosage, Oxonic Acid adverse effects, Recurrence, Tegafur administration & dosage, Tegafur adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy
- Abstract
S-1 is a novel oral anticancer agent consisting of tegafur, a prodrug of 5-fluorouracil, and 2 modulators. A phase I study of sequential S-1 and cyclophosphamide(CPA)therapy was conducted to determine the dose-limiting toxicities(DLTs)and recommended doses(RDs)in patients with metastatic or recurrent breast cancer(MBC). Patients with MBC received sequential S-1 and CPA. Chemotherapy consisted of administration of S-1 twice daily on days 1-14 at escalating doses of 40, 50, 65, and 80mg/m2/day and CPA at 100 mg/body/day on days 15-28. The schedule was repeated twice at a 4-week interval. The purposes of this study were to determine the RDs, safety, and efficacy of the regimen. A total of 12 patients were registered. No patients experienced DLTs, and the RDs of S-1 and CPA were 80mg/m2/day and 100 mg/body/day, respectively. The response rate was 50. 0%. In conclusion, sequential therapy with S-1 and CPA could be safely and effectively used for the treatment of MBC, and the RDs for this regimen were determined to be 80mg/m2/day for S-1 and 100 mg/m2/day for CPA.
- Published
- 2013
46. Diagnosis and surgical resection of solitary pulmonary nodules in patients with breast cancer.
- Author
-
Tanaka K, Shimizu K, Ohtaki Y, Nakano T, Kamiyoshihara M, Kaira K, Rokutanda N, Horiguchi J, Oyama T, and Takeyoshi I
- Abstract
The differential diagnosis of solitary pulmonary nodules (SPNs) using radiological features in patients with breast cancer is vital yet difficult. The nature of SPNs, of these patients, as well as the role of surgery in the diagnosis and treatment were evaluated. Thirty consecutive patients, who underwent surgery for an SPN between 2002 and 2011 subsequent to curative surgery for breast cancer were retrospectively evaluated. The overall survival and disease-free survival periods were estimated using the Kaplan-Meier method. The Student's t-test and the χ
2 test were performed to compare percentages and the mean values, respectively. The values were considered statistically significant at P<0.05. Most (93%) SPNs were malignant. The pathological diagnoses in patients with SPNs were primary lung cancer (n=20, 67%), pulmonary metastasis from breast (n=7, 23%) or colon (n=1, 3%) cancers and benign conditions (n=2, 7%). Of the 20 patients with primary lung cancer, 15 (75%) had stage IA tumors (T1aN0M0). The average disease-free interval was significantly longer in patients with primary lung cancer compared to patients with pulmonary metastases from breast cancer (P= 0.031). The five-year survival rates after pulmonary resection for lung metastasis from breast cancer patients and primary lung cancer patients were 100 and 61.1%, respectively. SPNs found in patients with breast cancer were found to have a high probability of malignancy, especially primary lung adenocarcinoma. The early resection of SPNs in patients diagnosed with both primary and metastatic lung cancer led to a good prognosis. The early pathological diagnosis by surgical resection was suggested to be conducted for the early diagnosis and appropriate treatment of SPNs in patients with breast cancer.- Published
- 2013
- Full Text
- View/download PDF
47. Collagen gel droplet-embedded culture-drug sensitivity test and Ki67 expression in estrogen receptor-positive and HER2-negative breast cancer.
- Author
-
Tozuka K, Horiguchi J, Takata D, Rokutanda N, Nagaoka R, Tokiniwa H, Kikuchi M, Satou A, Takei H, and Takeyoshi I
- Abstract
Anthracyclines and taxanes are standard anticancer drugs used in breast cancer chemotherapy. In general, the efficacy of chemotherapy is lower in patients with estrogen receptor (ER)-positive tumors compared to patients with ER-negative tumors. Although less chemosensitive, ER-positive disease includes a subset of patients who significantly benefit from adjuvant chemotherapy. The collagen gel droplet-embedded culture-drug sensitivity test (CD-DST) is an in vitro chemosensitivity test that has several advantages over conventional tests. The aim of the present study was to examine the correlation between CD-DST and the expression of Ki67, an indicator of tumor proliferation, to evaluate the efficacy of anthracyclines and taxanes in patients with ER-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. CD-DST was performed in 68 patients with ER-positive and HER2-negative breast cancer between August 2001 and November 2006. The specimens obtained during surgery were used for the CD-DST and immunohistological examination of Ki67 expression. Chemosensitivity to the anticancer drugs adriamycin (ADM), epirubicin (EPI), docetaxel (DOC) and paclitaxel (PTX) was estimated using CD-DST. Results obtained from the CD-DST showed the chemosensitivity to each anticancer drug to be ADM, 23.7%; EPI, 75.0%; DOC, 69.2% and PTX, 43.6%. Ki67 expression was significantly higher in the group that was sensitive to DOC compared to the group that was resistant to DOC (P=0.048) and PTX (P=0.036). In addition, a significant correlation was observed between a Ki67 labeling index (LI) of >30% and chemosensitivity to PTX. In conclusion, results obtained from CD-DST and Ki67 expression levels are able to identify a subset of patients with ER-positive and HER2-negative breast cancer who exhibit sensitivity to chemotherapy, particularly to taxane therapy.
- Published
- 2013
- Full Text
- View/download PDF
48. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
- Author
-
Tokiniwa H, Horiguchi J, Takata D, Kikuchi M, Rokutanda N, Nagaoka R, Sato A, Odawara H, Tozuka K, Oyama T, and Takeyoshi I
- Subjects
- Adult, Aged, Aged, 80 and over, Anthracyclines therapeutic use, Antigens, Neoplasm analysis, Biomarkers, Tumor analysis, Biomarkers, Tumor metabolism, Breast Neoplasms drug therapy, Breast Neoplasms mortality, DNA Topoisomerases, Type II analysis, DNA-Binding Proteins analysis, Female, Humans, Ki-67 Antigen analysis, Middle Aged, Predictive Value of Tests, Prognosis, Receptors, Progesterone metabolism, Retrospective Studies, Antigens, Neoplasm metabolism, Breast Neoplasms metabolism, Breast Neoplasms pathology, DNA Topoisomerases, Type II metabolism, DNA-Binding Proteins metabolism, Ki-67 Antigen metabolism, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism
- Abstract
Background: Topoisomerase II alpha (Topo IIa) is involved in DNA replication and is a molecular target for anthracycline-based chemotherapy. The Ki-67 labeling index (LI) is an evaluation of tumor cell proliferation. The objective of this study was to evaluate relationships among Topo IIa expression, the Ki-67 LI, and prognostic factors in estrogen receptor (ER)-positive, human epidermal growth factor type-2 (HER2)-negative breast cancer., Materials and Methods: Seventy-one patients were diagnosed with ER-positive, HER2-negative breast cancer between July 2003 and December 2004. Formalin-fixed, paraffin-embedded tumor specimens were stained for Topo IIa expression and Ki-67 LI. We investigated the correlation of the level of Topo IIa expression and the Ki-67 LI with clinical factors such as age, tumor size, progesterone receptor status, nodal status, nuclear grade, and lymphovascular invasion (LVI)., Results: Statistically significant differences were observed between Topo IIa overexpression, nuclear grade (p = 0.036), and LVI (p = 0.029). Topo IIa overexpression was statistically correlated with the Ki-67 LI (p < 0.0001). A statistically significant difference was observed between the Ki-67 LI and nuclear grade (p = 0.01). Survival analysis revealed the significant prognostic value of Ki-67 LI in patients with ER-positive, HER2-negative breast cancer (p = 0.003)., Conclusions: Ki-67 LI is a strong prognostic factor in ER-positive HER2-negative breast cancer. Topo IIa overexpression was significantly correlated with the Ki-67 LI, nuclear grade, and LVI. These findings suggest use of Topo IIa expression as a proliferation marker and a prognostic factor in ER-positive, HER2-negative breast cancer.
- Published
- 2012
- Full Text
- View/download PDF
49. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas.
- Author
-
Taguchi R, Yamada M, Nakajima Y, Satoh T, Hashimoto K, Shibusawa N, Ozawa A, Okada S, Rokutanda N, Takata D, Koibuchi Y, Horiguchi J, Oyama T, Takeyoshi I, and Mori M
- Subjects
- Adrenal Cortex Neoplasms metabolism, Adrenal Cortex Neoplasms pathology, Adrenal Cortex Neoplasms physiopathology, Adrenal Gland Neoplasms genetics, Adrenal Gland Neoplasms metabolism, Adrenocortical Adenoma metabolism, Adrenocortical Adenoma pathology, Adrenocortical Adenoma physiopathology, Adult, Aged, Base Sequence, Cross-Sectional Studies, Cushing Syndrome genetics, Cushing Syndrome metabolism, Female, G Protein-Coupled Inwardly-Rectifying Potassium Channels chemistry, Genetic Association Studies, Humans, Japan, Male, Middle Aged, Molecular Sequence Data, Neoplasm Proteins chemistry, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, Pheochromocytoma genetics, Pheochromocytoma metabolism, Retrospective Studies, Adrenal Cortex Neoplasms genetics, Adrenocortical Adenoma genetics, G Protein-Coupled Inwardly-Rectifying Potassium Channels genetics, G Protein-Coupled Inwardly-Rectifying Potassium Channels metabolism, Hyperaldosteronism etiology, Mutation, RNA, Messenger metabolism
- Abstract
Context: Mutations of the KCNJ5 gene have recently been identified in patients with aldosterone-producing adenomas (APA)., Objective: Our objective was to investigate the expression and mutations of the KCNJ5 gene in Japanese patients with APA., Design and Patients: We sequenced KCNJ5 cDNA and measured KCNJ5 mRNA levels in 23 patients with APA operated on at Gunma University Hospital., Main Outcome Measures: Mutations and mRNA levels of the KCNJ5 gene were examined and compared to those in cortisol-producing adenomas (Cushing's syndrome) and pheochromocytomas., Results: Of the 23 patients with APA, 15 (65.2%) had two somatic mutations of the KCNJ5 gene: 12 cases of p.G151R (eight with c.451G>A, and four with c.451G>C) and three cases of p.L168R (c.503T>G). Levels of KCNJ5 mRNA were significantly higher in the APA with mutations than those without. Immunohistochemistry also showed a stronger staining of KCNJ5 on the cell membrane in the tumor with a mutation. Furthermore, a PCR-restriction fragment length polymorphism assay with c.503T>G revealed the mutant mRNA to be expressed at a similar level to the wild type. The level of KCNJ5 mRNA in cortisol-producing adenomas was approximately 30% of that in APA, and almost no expression was observed in pheochromocytomas., Conclusion: We found that: 1) a significant number of patients with APA had somatic mutations of the KCNJ5 gene; 2) KCNJ5 mRNA levels were higher in the APA with KCNJ5 mutations; and 3) the expression of KCNJ5 mRNA was significantly higher in APA than cortisol-producing adenomas and pheochromocytomas.
- Published
- 2012
- Full Text
- View/download PDF
50. Papillary lesions of the breast diagnosed using core needle biopsies.
- Author
-
Tokiniwa H, Horiguchi J, Takata D, Kikuchi M, Rokutanda N, Nagaoka R, Sato A, Odawara H, Tozuka K, Oyama T, and Takeyoshi I
- Abstract
Papillary lesions of the breast include a broad spectrum of lesions, from benign papillomas to papillary carcinomas. It is difficult to determine whether a lesion is benign or malignant based on the fragmented material of a core needle biopsy (CNB). This study evaluated patients with papillary lesions examined using CNB. We retrospectively reviewed 31 papillary lesions diagnosed using CNB between 2004 and 2007. The clinical findings of benign and malignant papillary lesions were compared. The average patient age was 48.9 years. Twelve patients presented with a discharge and 10 patients presented with a lump. Eight patients were asymptomatic. The initial diagnoses by CNB of the 31 lesions were 25 intraductal papillomas, 4 intracystic papillomas and 2 adenomas. After CNB, excisional biopsies were performed in 23 patients and biopsies with a Mammotome(®) in 2 patients. Seven patients underwent regular follow-up. Five (16%) of the 31 patients with papillary lesions were ultimately diagnosed with breast cancer. The average distance from the nipple to a tumor diagnosed as malignant was 2.46 cm, which was longer than for a tumor diagnosed as benign. Ultimately, 5 papillary lesions (16%) were diagnosed as breast cancer. To avoid overlooking a malignancy, surgical excision is advantageous for papillary lesions, particularly those located far from the nipple.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.